Inorganic Nitrate Supplementation on Cerebrovascular Aging and Arterial Stiffness Study (INCA)

Effects of Inorganic Nitrate Supplementation on Cerebrovascular Aging and Arterial Stiffness Study

This study investigates the effect of dietary inorganic nitrate supplementation on 1) large elastic artery stiffness and hemodynamics and 2) cerebrovascular function in middle-aged and older adults. Participants will be randomized to consume either nitrate-containing or nitrate-depleted beetroot juice.

Study Overview

• Status: Active, not recruiting
• Conditions: Hypertension; Aging; Endothelial Dysfunction; Cognitive Decline; Arterial Stiffness
• Intervention / Treatment: Drug: Experimental: Nitrate-containing; Drug: Placebo: Nitrate-depleted

Detailed Description

Reduced nitric oxide bioavailability with aging contributes in part to increased large central artery stiffness and cerebrovascular dysfunction. Large central artery stiffness is a risk factor for cognitive decline mediated in part by the development of cerebrovascular dysfunction. This study will investigate the degree to which improving nitric oxide bioavailability using dietary inorganic nitrate supplementation improves cerebrovascular function through reductions in large central artery stiffness in middle-aged and older adults.

• Study Type: Interventional
• Enrollment (Actual): 53
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Gary L Pierce, PhD; Phone Number: (319)335-9487; Email: gary-pierce@uiowa.edu
• Study Contact Backup: Name: Amy Stroud, RN; Phone Number: 3193562710 (319)356-2710; Email: amy-stroud@uiowa.edu

Study Locations

• United States
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • University of Iowa

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years to 79 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age 50-79 years
• Cognitively healthy, having mild cognitive impairment
• Able to undergo cardiovascular testing procedures including fasting overnight and holding selected morning medication doses.
• Ability to understand and willingness to sign a written informed consent document.
• Ability to lie comfortably for up to 90 minutes
• Women only: Post-menopausal

Exclusion Criteria:

• Current or history of cardiovascular disease disease (heart attack, stroke, heart failure, cardiomyopathy or peripheral artery disease, heart angioplasty/stent or bypass surgery, valve replacement, carotid endarterectomy, heart transplant.
• Medical history of stroke or other neurological disorder or systemic illness that could potentially affect cognition or brain function (outside of a diagnosis of Mild Cognitive impairment, Alzheimer's Disease) or could affect their safety or comfort while undergoing the imaging or cardiovascular studies.
• Subjects with evidence of cardiovascular disease at baseline or during the exercise test (evidence of myocardial infarction, abnormal cardiac arrhythmia, myocardial ischemia, conduction delays, >1mm S-T segment depression or elevation; >3 beat ventricular tachycardia; atrial fibrillation) will be excluded from the study.
• Wilson's disease, hemochromatosis
• Individuals taking clonidine or other short-acting beta blocker
• Resting blood pressure > 200/ 110 mmHg or systolic <90 mmHg
• Medical history of chronic major psychiatric or current diagnosis of major psychiatric disease (other than dementia).
• Systemic illness or neurological disorder potentially affecting cognition or cerebral blood flow other than mild cognitive impairment
• Unable to provide informed consent due to cognitive impairment
• Currently taking medications that may affect cerebral blood flow (e.g. papaverine, indomethacin, acetazolamide, etc) or efficacy of beetroot juice (proton pump inhibitors)
• Current clinically abnormal thyroid function not adequately regulated by thyroid hormone supplementation or medication.
• Allergic to beets
• Current tobacco user or history of tobacco use within the past 3 months (cigarettes, cigars, chewing tobacco, hookah, electronic cigarettes) or living with someone who smokes/has smoked in the past 3 months.
• Current diagnosis of insulin-dependent diabetes (Type I or insulin dependent Type II)
• Current diagnosis of chronic obstructive lung disease, cystic fibrosis, emphysema, chronic bronchitis
• History of renal failure, dialysis or kidney transplant
• Current diagnosis or history of liver disease or HIV/AIDS, or cancer (other than non-melanoma skin cancers).
• Current diagnosis or history of rheumatoid arthritis, systemic lupus erythematosus, Wegener's granulomatosis
• Vulnerable populations (prisoners, etc) will not be eligible.
• Unwillingness to wash out from a vitamin or dietary supplement regime prior to enrollment and maintain throughout the duration of the study.
• Inability to comply with experimental instructions.
• Uncontrolled intercurrent illness that would limit compliance with study requirements per investigator.
• Inability to fast or hold morning medications doses until after testing is complete.
• Hormone replacement use within the past 6 months
• Currently enrolled in another study using an study medication, supplement, device or intervention.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Beetroot juice; 10-grams of nitrate-containing beetroot concentrate diluted in 120-180 milliliters of water.	Drug: Experimental: Nitrate-containing; Experimental
Placebo Comparator: Placebo Beetroot juice; 10 grams of nitrate-depleted beetroot concentrate balanced for anti-oxidant content diluted in 120-180 milliliters of water.	Drug: Placebo: Nitrate-depleted; Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acute change in carotid artery stiffness	Common carotid artery stiffness measured by ultrasonography and applanation tonometry.	2-hours
Acute change in cerebral blood flow	Large cerebral artery blood flow will be measured using 4-Dimensional (4D) phase contrast vastly undersampled isotropic projection imaging (pcVIPR) magnetic resonance imaging (MRI).	2-hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Internal carotid artery endothelium-dependent dilation	Endothelium-dependent dilation of the internal carotid artery in response to hypercapnia will be measured using ultrasonography.	2-hours

Collaborators and Investigators

• Sponsor: Gary L. Pierce
• Collaborators: University of Wisconsin, Madison
• Investigators: Principal Investigator: Gary Pierce, PhD, University of Iowa

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2018
• Primary Completion (Actual): December 30, 2022
• Study Completion (Anticipated): June 30, 2024

Study Registration Dates

• First Submitted: July 30, 2018
• First Submitted That Met QC Criteria: August 3, 2018
• First Posted (Actual): August 6, 2018

Study Record Updates

• Last Update Posted (Actual): May 24, 2023
• Last Update Submitted That Met QC Criteria: May 22, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: Cerebral Small Vessel Disease; Cerebrovascular function; Cerebral blood flow; Beetroot juice; Cerebrovascular Reserve; Neurovascular Coupling; Pulsatility; Carotid artery stiffness; Dietary Inorganic Nitrate Supplementation
• Additional Relevant MeSH Terms: Mental Disorders; Neurocognitive Disorders; Cognition Disorders; Cognitive Dysfunction
• Other Study ID Numbers: 201805720

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes